Hepatitis A virus vaccination in persons with hepatitis C virus infection: Consequences of quality measure implementation

Hepatology

Volumn 56, Issue 2, 2012, Pages 501-506

  Rowe, Ian A ^a,b   Parker, Richard ^a,b   Armstrong, Matthew J ^a,b   Houlihan, Diarmaid D ^a,b   Mutimer, David J ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VACCINE;

ARTICLE; DISEASE SURVEILLANCE; DRUG COST; DRUG EFFICACY; FATALITY; HEALTH CARE QUALITY; HEPATITIS A; HEPATITIS A VIRUS VACCINATION; HEPATITIS C; HUMAN; INCIDENCE; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SUPERINFECTION; VACCINATION;

HEALTH CARE COSTS; HEPATITIS A; HEPATITIS A VACCINES; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; QUALITY INDICATORS, HEALTH CARE; RISK FACTORS; SUPERINFECTION;

EID: 84864342570     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25683     Document Type: Article

References (41)

1. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-521.
2. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331-338.
3. Kappelman MD, Dorn SD, Peterson E, Runge T, Allen JI. Quality of care for gastrointestinal conditions: a primer for gastroenterologists. Am J Gastroenterol 2011; 106: 1182-1187.
4. Physician Quality Reporting System. Quality Measures List. 2011. Available at: Accessed November 30, 2011.
5. Kramer JR, Hachem CY, Kanwal F, Mei M, El-Serag HB. Meeting vaccination quality measures for hepatitis A and B virus in patients with chronic hepatitis C infection. HEPATOLOGY 2011; 53: 42-52.
6. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9: 524-530.
7. Almasio PL, Amoroso P. HAV infection in chronic liver disease: a rationale for vaccination. Vaccine 2003; 21: 2238-2241.
8. Keeffe EB. Acute hepatitis A and B in patients with chronic liver disease: prevention through vaccination. Am J Med 2005; 118(Suppl 10A): 21S-27S.
9. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012.
10. Review Manager RevMan version 5.1 [computer program]. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. 2011.
11. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
12. Sweeting, MJ, Sutton, AJ, Lambert, PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 2004; 23: 1351-1375.
13. Trial Sequential Analysis, version 0.9 beta [computer program]. Copenhagen Trial Unit. 2011.
14. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-714.
15. Kelly H, Attia J, Andrews R, Heller RF. The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over. Vaccine 2004; 22: 2192-2198.
16. Sjogren MH. Preventing acute liver disease in patients with chronic liver disease. HEPATOLOGY 1998; 27: 887-888.
17. Keeffe EB, Iwarson S, McMahon BJ, Lindsay KL, Koff RS, Manns M, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. HEPATOLOGY 1998; 27: 881-886.
18. Jacobs RJ, Koff RS, Meyerhoff AS. The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A. Am J Gastroenterol 2002; 97: 427-434.
19. Vaccines: VFC/CDC Vaccine Price List. Available at: Accessed November 30, 2011.
20. Leino T, Pebody R, Leinikki P. Hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338: 1772.
21. Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338: 286-290.
22. Hasle G, Hoel T, Jensenius M. Mortality of hepatitis A in adults with hepatitis C antibodies. Lancet 1998; 351: 1888.
23. Mele A, Tosti ME, Stroffolini T. Hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338: 1771.
24. Battegay M, Naef M, Bucher HC. Hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338: 1771-1772.
25. Helbling B, Renner EL, Kammerlander R. Acute hepatitis A in patients with chronic hepatitis C. Ann Intern Med 1999; 131: 314.
26. Pramoolsinsap C, Poovorawan Y, Hirsch P, Busagorn N, Attamasirikul K. Acute, hepatitis-A super-infection in HBV carriers, or chronic liver disease related to HBV or HCV. Ann Trop Med Parasitol 1999; 93: 745-751.
27. Bianco E, Stroffolini T, Spada E, Szklo A, Marzolini F, Ragni P, et al. Case fatality rate of acute viral hepatitis in Italy: 1995-2000. An update. Dig Liver Dis 2003; 35: 404-408.
28. Spada E, Genovese D, Tosti ME, Mariano A, Cuccuini M, Proietti L, et al. An outbreak of hepatitis A virus infection with a high case-fatality rate among injecting drug users. J Hepatol 2005; 43: 958-964.
29. Deterding K, Tegtmeyer B, Cornberg M, Hadem J, Potthoff A, Boker KH, et al. Hepatitis A virus infection suppresses hepatitis C virus replication and may lead to clearance of HCV. J Hepatol 2006; 45: 770-778.
30. CDC DVH-Viral Hepatitis Statistics & Surveillance-United States, 2009. Available at: Accessed November 30, 2011.
31. Compressed Mortality File on CDC WONDER. Available at: 2011. Accessed November 30, 2011.
32. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. HEPATOLOGY 2009; 49: 1335-1374.
33. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264.
34. Recommended adult immunization schedule: United States, 2011. Ann Intern Med 2011; 154: 168-173.
35. Vogt TM, Wise ME, Bell BP, Finelli L. Declining hepatitis A mortality in the United States during the era of hepatitis A vaccination. J Infect Dis 2008; 197: 1282-1288.
36. Wise M, Bialek S, Finelli L, Bell BP, Sorvillo F. Changing trends in hepatitis C-related mortality in the United States, 1995-2004. HEPATOLOGY 2008; 47: 1128-1135.
37. Myers RP, Gregor JC, Marotta PJ. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C. HEPATOLOGY 2000; 31: 834-839.
38. Arguedas MR, Heudebert GR, Fallon MB, Stinnett AA. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C viral infection in the United States. Am J Gastroenterol 2002; 97: 721-728.
39. Jacobsen KH. The global prevealence of hepatitis A virus infection and susceptability: a systematic review. Geneva, Switzerland: World Health Organization; 2009.
40. Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. BMJ 1999; 318: 527-530.
41. Rowe IA, Mutimer DJ. Protease inhibitors for treatment of genotype 1 hepatitis C virus infection. BMJ 2011; 343: d6972.